Toggle navigation
About Us
Business Areas
R & D
Manufacturing
Beyond Business
Investors
Careers
Contact Us
Investors
Investors > FY 2024-25
Overview
Chairman's Statement
Shareholder Information
Policies or Statutory Documents
IEPF
Debentures
Amalgamation
MOA/AOA
Procedure for Dematerialisation of Shares
Archives
Credit Ratings
CSR
AGM Transcript
Annual Return
Disclosures under Regulation 46 and 62 of SEBI LODR
Financial
2024-25
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
2016-17
2015-16
2014-15
2013-14
2012-13
2011-12
Investors > FY 2024-25
1. Intimation to Stock Exchange
Intimation for Trading Window Closure_Q1
Newspaper advertisement regarding Intimation of the 51st AGM of the Company through VC / OAVM facility
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize its Novel Gastrointestinal Drug in India
Intimation for Concall with Investors / Analyst Q4_2023-24
Intimation of the Board Meeting dated 24-05-2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Cessation of Directors of the Company
Details of Nodal Officer
Name
: Chintan Trivedi
Designation
: Company Secretary
E-mail Id
: investorservices@torrentpharma.com
IEPF Authority - Refund web page
IEPF Authority - Refund web page >>
